louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01040234: Bilateral Dual TAP Block: Description of a Novel Four-point Approach
Official title: Ultrasound-guided Bilateral Dual Transversus Abdominis Plane (BD-TAP) Block: Description of a Novel Four-point Ultrasound-guided TAP Block Approach
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Postoperative Pain
Keywords: postoperative pain
abdominal surgery
bilateral dual TAP block
Lead sponsor: Bispebjerg Hospital
Sponsor class: OTHER
First posted: 2009-12-29
Enrollment: 30
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with postoperative pain following abdominal surgery that do not respond to moderate doses of opioid analgesics or patients with failed epidurals

Brief summary: A prospective study of 30 patients with severe postoperative pain following abdominal surgery, in which the dual TAP block technique has been used successfully to achieve pain relief. A description of ultrasound technique, effectiveness, duration and potential side effects of the pain treatment, with possible recommendations for future use.

Detailed description: This prospective cohort study is designed to describe a novel ultrasound-guided bilateral dual transversus abdominis plane (BD-TAP) block and to evaluate the postoperative analgesic efficacy in a selection of patients having undergone major abdominal surgery under general anaesthesia where neuraxial anaesthesia and/or intravenous administration of analgesics had failed or was unwanted by the patient, or if the placement of an epidural catheter was deemed impossible by the anaesthetist in charge. 30 consecutive patients planned for the study. BD-TAP to be performed bilaterally with a high frequency linear ultrasound probe, with bupivacaine. Success rate, decline in VAS score, postoperative demand of opioids and block performance time to be recorded.

Eligibility criteria: Inclusion Criteria:

* Patients with pain VAS \>5 following abdominal surgery, in which conventional pain treatment or epidural block is either ineffective or contraindicated

Exclusion Criteria:

* Hypersensitivity to local anaesthetics

Primary outcomes:
measure: Pain VAS after the intervention compared to pre-intervention VAS
timeFrame: 10-20 minutes after intervention
Secondary outcomes:
measure: Pain medication required following intervention
timeFrame: First 24 hours
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Dept Z, Bispebjerg Hospital
state: Copenhagen NV
Study officials:
affiliation: Dept Z, Bispebjerg Hospital
name: Jens N Børglum, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02803034: Sun Protection Factor Assay
Official title: Sun Protection Factor (SPF) Assay UVA Protection Factor Assay (UVAPF) Minimal Persistent Pigment - Darkening Dose (MPPD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreening Agent
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-06-16
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the Sun Protection Factor efficacy on human skin.


Eligibility criteria: Inclusion Criteria:

* Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
* Male and female
* Aged between 18-70 years old.
* Good health as determined from the HRL SHF(Self History Form)
* Signed and dated Informed Consent Form
* Signed and dated HIPAA (Health Insurance Portability and Accountability Act) Form
* An unambiguous MED (Minimal Erythema Dose) or MPPD (Minimal Persistent Pigment Darkening Dose)

Exclusion Criteria:

* Subjects on test at any other research laboratory or clinic.
* Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
* Pre-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
* Pre-existing other medical conditions (e.g. adult asthma. diabetes).
* Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
* Treatment with antibiotics within two weeks prior to initiation of the test.
* Chronic medication which could affect the results of the study.
* Known pregnant or nursing women.

Primary outcomes:
measure: Minimal Erythema Dose (MED)
timeFrame: Up to 15 minutes
measure: Minimal Persistent Pigment Darkening Dose (MPPD)
timeFrame: Up to 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Union
country: United States
state: New Jersey
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT05768334: Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease
Official title: Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: NAFLD
Lead sponsor: Helwan University
Sponsor class: OTHER
First posted: 2023-03-14
Enrollment: 116
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objectives To evaluate the efficacy, safety, and tolerability of lubiprostone in patients with nonalcoholic fatty liver disease (NAFLD).

This study will include 100 patients with nonalcoholic fatty liver disease (NAFLD) recruited from the specialized NAFLD outpatient's clinic in National Hepatology and Tropical Medicine Research Institute (NHTMRI).

Study design: Randomized controlled trial.


Eligibility criteria: Inclusion Criteria:

- 1. Age from 18-65 years. 2. Cases with NAFLD suspected by abdominal ultrasound or CT. 3. Negative viral hepatitis markers (Hepatitis B surface Antigen \&Hepatitis C virus Antibody).

4. Negative autoantibodies (Antinuclear Antibody). 6. Non-cirrhotic patients as diagnosed by fibroScan (F4\<14.6KPa). 7. Hepatic steatosis \> 5% with MRI-PDFF.

Exclusion Criteria:

* 1. History of other forms of liver disease (including viral hepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease, and alpha-1-antitrypsin disease).

  2. Alcohol intake exceeding 30 g/day in the last 10 years or exceeding 10 g/day in the previous year (Saunders et al., 1993).

  3. Child-Pugh score \> 7. 4. Cirrhotic patients diagnosed by fibroScan (F4\>14.6KPa) 5. Calculated Estimated Glomerular Filtration Rate (eGFR) \<60 mL/min/1.73m2. 6. Pregnancy. 7. Evidence of hepatocellular carcinoma as stated by Barcelona Clinic Liver Cancer (BCLC) (Llovet et al., 2003).

  8. Contraindications to MRI: prostetic heart valves and annuloplasty rings, metallic implants, patients who have peacemaker, and contrast allergy.

Primary outcomes:
measure: MRI-PDFF (the magnetic resonance imaging-estimated proton density fat fraction).
timeFrame: 48 weeks
Secondary outcomes:
measure: FibroScan with CAP (Controlled Attenuation Parameter)
timeFrame: 48 weeks
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: National Hepatology and Tropical Medicine Research Institute
Study officials:
References:
Clinical trial NCT04162834: Effect of Papaverine on Renal Artery Blood Flow Volume
Official title: Effect of Papaverine on Intraoperative Renal Artery Blood Flow Volume in Patients Undergoing Robot-assisted Partial Nephrectomy : a Randomized, Placebo-controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Kidney Cancer
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2019-11-14
Enrollment: 96
Sex: ALL
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study is to evaluate the effect of papaverine on renal artery blood flow after declamping of renal artery.

Detailed description: The purpose of this study is to evaluate the effect of papaverine on renal artery blood flow after declamping of renal artery in patients undergoing robot assisted partial nephrectomy.

Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with kidney cancer.
* Patients undergoing robot assisted partial nephrectomy under general anesthesia
* 20 years old ≤ age \<80 years old
* Patients who voluntarily agreed to this clinical study
* eGFR ≥ 60 ml / min / 1.73 m2 (Chronic Kidney Disease Epidemiology Patients with Collaboration)

Exclusion Criteria:

* The tumor ≥ 7 cm in size
* Multiple renal mass
* If the surgery plan is changed due to open
* When surgery is performed together with other surgery
* Multiple renal artery
* Patients with hypersensitivity to papaverine
* Patients with atrioventricular block
* Pregnant and lactating women
* Patients using levodopa
* Refusal of patient

Primary outcomes:
measure: Renal artery blood flow
timeFrame: at 2 minutes after papaverine administration
Secondary outcomes:
measure: estimated glomerular filtration rate
timeFrame: at postoperative day 0
measure: estimated glomerular filtration rate
timeFrame: at postoperative day 1
measure: estimated glomerular filtration rate
timeFrame: at postoperative day 4
measure: estimated glomerular filtration rate
timeFrame: at postoperative day 14
measure: estimated glomerular filtration rate
timeFrame: at postoperative month 3
measure: glomerular filtration rate using renal scan
timeFrame: at postoperative month 3
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan medical Center
Study officials:
affiliation: Asan Medical Center
name: Young-Kug Kim, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00492934: What is the Best Preparation for Embryo Transfer in Cryo Cycles: a Natural Cycle or Light Hormonal Stimulation?
Official title: Natural Cycle Versus Stimulation With Human Menopausal Gonadotropin in Cycles With Cryopreserved Embryos
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Infertility
Keywords: subfertility
endometrium thickness
implantation rate
embryo cryopreservation
embryo transfer
Lead sponsor: University Hospital, Gasthuisberg
Sponsor class: OTHER
First posted: 2007-06-27
Enrollment: 300
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study investigates if, among women with a regular cycle (between 25 and 45 days), the endometrium is better prepared for the transfer of an embryo that was cryopreserved and if the subsequent embryo implantation rate is higher when the cycle is started with daily, small-dose hormonal injections than in cycles without these daily injections.


Eligibility criteria: Inclusion Criteria:

* Signed informed consent.
* Women with a regular cycle (between 21 and 35 days).
* Embryos with 50% intact blastomeres after thawing.
* Embryo and endometrium are synchronized.

Exclusion Criteria:

* Embryo storage time not longer than 5 years.

Primary outcomes:
measure: implantation rate per embryo
timeFrame: 15 days after the embryo transfer
Secondary outcomes:
measure: thickness of the endometrium
timeFrame: 0-2 days before the human chorionic gonadotropin (hCG) injection
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: Leuven University Fertility Center
state: Vlaams Brabant
Study officials:
affiliation: University Hospital Gasthuisberg, Catholic University Leuven, Belgium
name: Thomas D'Hooghe, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Peeraer K, Couck I, Debrock S, De Neubourg D, De Loecker P, Tomassetti C, Laenen A, Welkenhuysen M, Meeuwis L, Pelckmans S, Meuleman C, D'Hooghe T. Frozen-thawed embryo transfer in a natural or mildly hormonally stimulated cycle in women with regular ovulatory cycles: a RCT. Hum Reprod. 2015 Nov;30(11):2552-62. doi: 10.1093/humrep/dev224. Epub 2015 Sep 12.
Clinical trial NCT04210934: Study of Microbiota in Longevity County, Yongfu
Official title: Study of the Feature of Intestinal Microbiota and Its Role in Healthy Aging in Southern Chinese From a Longevity County, Yongfu
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aging
Healthy Aging
Keywords: Microbiota
multi-omics
Lead sponsor: Beijing Hospital
Sponsor class: OTHER_GOV
Collaborators: name: BGI-Shenzhen
First posted: 2019-12-26
Enrollment: 160
Sex: ALL
Minimum age (years): 22
Maximum age (years): 111
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The current study was based on the Longevity and Health of Aging Population in Guangxi China (LHAPGC) study conducted in Yongfu County (qualified as the longevity town by Geriatric Society of China) in 2016.The enrolled subjects do not rely on medical care and do not take antibiotics recently. They are representative of a natural healthy-aging population model .

Brief summary: This study is an observational study designed to adopt a cross-sectional study design. In the context of China's longevity town (East Asian population), Yongfu, Guangxi, the background of non-medical care and antibiotic use was explored, and the intestinal microecological balance increased with age and natural health. Longevity relationship. This study was completed using a household survey. Through routine clinical examinations and analysis of biochemical laboratory indicators, at the same time, a questionnaire for ADL(activities of daily living), cognitive function, and related elderly information was carried out on the elderly to comprehensively provide health information for each elderly. Based on the remaining stool samples and serum samples, the second-generation sequencing technology and other omics-based technologies were explored. No additional collection of human specimens and information is involved.

In addition, this study also hopes to explore the transmission rules of age-related bacteria in long-lived families, and the relationship with health phenotypes such as blood sugar, blood lipids, and cognitive function. Potential impact. In summary, this study will provide data support for exploring the relationship between healthy longevity and intestinal microecological balance based on the characteristic population of the longevity hometown.


Eligibility criteria: Inclusion Criteria:

* Obtained informed consent signed by volunteer or guardian
* Local lived for more than 50 years

Exclusion Criteria:

* Subjects being treated with antibiotic in 3 months
* People who cannot cooperate with completing the survey
* Severe gastrointestinal disorders

Primary outcomes:
measure: Aging-related fecal microbiota annotation
timeFrame: 0 week
Secondary outcomes:
measure: interface of microbiota and other biomarkers in aging and related conditions
timeFrame: 0 week
Other outcomes:
Locations:
Study officials:
affiliation: Beijing Hospital
name: Liang Sun, Ph.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Beijing Hospital
name: Ze Yang, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT01483534: Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation
Official title: Evaluation of the Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation (TLD) Therapy in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) - A Safety Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Keywords: Chronic Obstructive Pulmonary Disease
Pulmonary
Intervention
Device
Denervation
Lung
Holaira, Inc.
Innovative Pulmonary Solutions, Inc.
Lead sponsor: Nuvaira, Inc.
Sponsor class: INDUSTRY
First posted: 2011-12-01
Enrollment: 22
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety of Targeted Lung Denervation Therapy (or TLD TherapyTM) in patients suffering from COPD. Technical feasibility of the IPS SystemTM will also be evaluated through confirmation of successful application of TLD Therapy.


Eligibility criteria: Inclusion Criteria:

* FEV1 30% to 60%
* FEV1/FVC \<70%
* Prior smoker (at least 10 pack years)
* Quit smoking for at least 6 months

Exclusion Criteria:

* Pulmonary hypertension, peripheral edema suggesting CHF or polycythemia
* Prior lung transplant, LVR, LVRS, median sternotomy, bullectomy or lobectomy
* Pulmonary nodule requiring surgery
* Presence of implantable electronic devices
* Active respiratory infection within recent weeks
* COPD exacerbation within recent weeks
* Recent Myocardial infarction (MI)
* Recent and unstable or life threatening arrhythmia
* Malignancy treated with radiation or chemotherapy within the last 2 years
* Presence or clinical diagnosis of other respiratory diseases other than COPD

Primary outcomes:
measure: Primary Safety Endpoint
timeFrame: 365 days post procedure
Secondary outcomes:
measure: Technical Feasibility
timeFrame: At time of Treatment
Other outcomes:
Locations:
city: Groningen
country: Netherlands
facility: University Medical Center Groningen (UMCG)
city: Panorama
country: South Africa
facility: Panorama Medi-Clinic
state: Cape Town
city: Capetown
country: South Africa
facility: Stellenbosch University
Study officials:
affiliation: University Medical Center Groningen
name: Dirk-Jan Slebos, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Slebos DJ, Klooster K, Koegelenberg CF, Theron J, Styen D, Valipour A, Mayse M, Bolliger CT. Targeted lung denervation for moderate to severe COPD: a pilot study. Thorax. 2015 May;70(5):411-9. doi: 10.1136/thoraxjnl-2014-206146. Epub 2015 Mar 4.
Clinical trial NCT04763317: Precision Medicine in the Prostate Cancer Care Pathway
Official title: Precision Medicine in the Prostate Cancer Care Pathway: an Evaluation of Integrating Germline Genetic Testing Into the Management of Men at Risk of / Living With Prostate Cancer
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Prostate Cancer
Genetic Predisposition
Lead sponsor: Institute of Cancer Research, United Kingdom
Sponsor class: OTHER
Collaborators: name: Royal Marsden NHS Foundation Trust
First posted: 2021-02-21
Enrollment: 2000
Sex: MALE
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: There are two pathways for men to be approached about this study; first eligible men will be identified and approached by their clinical team in Urology and Uro-Oncology clinics at the Royal Marsden. Second, men already under the care of the Oncogenetics Research team due to their family history of prostate cancer and who meet the eligibility criteria will be given information about the study as deemed appropriate by the research clinician who has been managing their care (Research Nurse or Clinical Research Fellow).

Brief summary: This study aims to evaluate the use of a prostate cancer specific predisposition genetic panel test in men with / at high risk of prostate cancer. The genetic test will analyse men's DNA samples for the presence of mutations in rare genes as well as common genetic variation to provide men with information about their risk of prostate cancer. This study will evaluate the clinical impact of the test on risk assessment and clinical management in terms of screening and treatment.


Eligibility criteria: Inclusion Criteria:

Affected cohort:

1. Affected with PrCa \< 70 years or
2. Affected with metastatic castration resistant PrCa (mCRPC) at any age or
3. Affected with PrCa and a family history defined as

   1. two or more cases in family with one case \< 70
   2. three or more cases any age (FDR or SDR)

Unaffected cohort:

Aged \>30 and with a family history defined as:

1. FDR diagnosed \< 70
2. 2 or more cases in First or Second Degree Relatives (FDR/SDR) with one case diagnosed \< 70 years
3. 3 or more cases at any age (on same side of family)

Exclusion Criteria:

* • WHO performance status 4

Primary outcomes:
measure: Prevalence of genetic variation in affected men
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
measure: Prevalence of genetic variation in unaffected men
timeFrame: Through study completion, an average of 1 year
measure: Prostate Cancer genetic variation on clinical outcome
timeFrame: Through study completion, an average of 1 year
Other outcomes:
Locations:
city: Sutton
country: United Kingdom
facility: Royal Marsden Hosital,
state: England
Study officials:
References:
Clinical trial NCT03512717: Efficacy and Safety of Potenfill for Temporary Penile Enhancement
Official title: A Multi-center, Randomized, Subject-evaluator Blind, Active Controlled Design Clinical Study to Determine the Efficacy and Safety of Potenfill for Temporary Penile Enhancement
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Penile Enhancement
Lead sponsor: Medy-Tox
Sponsor class: INDUSTRY
First posted: 2018-05-01
Enrollment: 76
Sex: MALE
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evlauate the efficacy and safety of poteinfill, compared to the powerfill.


Eligibility criteria: Inclusion Criteria:

1. Male subjects aged above 19 and below 65. (20≤male≥65)
2. be rating himself, when screening, as "Small or Very Small" on Self-Questioned Questionnaire ( SQQ) including the question: " How do you rate your penile size? // Very small, Small, Normal, Big, Very Big?"
3. Subjects will sign an informed consent form

Exclusion Criteria:

1. Prior treatment for penile enhancement (e.g. fat, dermal graft).
2. Subjects who have penile malformation (e.g. Peyronie's disease), which can make impossible to perform the intervention
3. Allergic to hyalluronic acid.
4. Inflammatory or/and infectious disease on penis that can affect on this study

Primary outcomes:
measure: the Penile Circumference difference at 24 weeks from baseline
timeFrame: 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Gangdong Sacred Heart Hospital, Hallym Univ
Study officials:
References: